Zaloguj się

Gotowe bibliografie tematyczne / Dose secondaire / Artykuły w czasopismach

Artykuły w czasopismach na temat „Dose secondaire”

Kliknij ten link, aby zobaczyć inne rodzaje publikacji na ten temat: Dose secondaire.

Autor: Grafiati

Data publikacji: 20 lipca 2024

Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych

Wybierz rodzaj źródła:

Sprawdź 50 najlepszych artykułów w czasopismach naukowych na temat „Dose secondaire”.

Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.

Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.

Przeglądaj artykuły w czasopismach z różnych dziedzin i twórz odpowiednie bibliografie.

1

Berkebile, G., P. Raymond, T. Cuffaro Piscitello, O. Vandevelde, M. Klein i N. Scheyer. "Neutropénie, un potentiel effet secondaire de l’osilodrostat à forte dose". Annales d'Endocrinologie 84, nr 1 (luty 2023): 134. http://dx.doi.org/10.1016/j.ando.2022.12.129.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

2

Baline, K., F. Hali, M. El Bouz, J. Hachim, K. El Maani i H. Benchikhi. "Érythème acral bulleux secondaire à un traitement par méthotrexate à forte dose". Annales de Dermatologie et de Vénéréologie 140 (kwiecień 2013): S91. http://dx.doi.org/10.1016/j.annder.2013.01.164.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

3

Canonne-Guibert, Morgane. "Traitement du diabète sucré : choisir l’insuline la plus adaptée (type, dose, fréquence)". Le Nouveau Praticien Vétérinaire canine & féline 20, nr 86 (2023): 8–14. http://dx.doi.org/10.1051/npvcafe/2024015.

Pełny tekst źródła

Streszczenie:

Le diabète sucré est une endocrinopathie se définissant par une insuffisance absolue en insuline (chez le chien) ou une insuffisance relative (secondaire à une glucotoxicité, chez le chat), à l’origine d’un déséquilibre dans l’homéostasie glucidique. L’insulinothérapie est l’une des pierres angulaires de la prise en charge thérapeutique d’un chien ou d’un chat diabétique. Le clinicien doit alors relever le défi de prescrire l’insuline la plus adaptée et ce choix repose, le plus souvent, sur la considération de l’espèce (chat vs chien), la situation clinique (acidocétose vs diabète sucré stable, existence de comorbidités occasionnant une insulinorésistance) et la possibilité ou non d’une administration par un stylo injecteur. Enfin, une évolution clinique et biologique peu satisfaisante peut conduire le praticien à choisir une insuline de 2de intention selon certains critères (durée d’action différente, correction d’une grande variabilité glycémique).

Style APA, Harvard, Vancouver, ISO itp.

4

Hulin, C., E. Renoult, J. Champigneulle, L. Clément, M. Kessler i P. Lederlin. "Évolution favorable d'une glomérulonéphrite secondaire à une cryoglobulinémie de type I après melphalan haute dose suivi d'autogreffe". La Revue de Médecine Interne 21 (grudzień 2000): 560. http://dx.doi.org/10.1016/s0248-8663(00)90190-5.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

5

de Revel, T., T. Fagot, B. Souleau, D. Dormont i G. Nedellec. "L'aplasie médullaire secondaire à un accident d'irradiation: options thérapeutiques et évolution des concepts". Canadian Journal of Physiology and Pharmacology 80, nr 7 (1.07.2002): 694–99. http://dx.doi.org/10.1139/y02-095.

Pełny tekst źródła

Streszczenie:

Bone marrow grafting following accidental irradiation exposure should be viewed in the perspective of a severe myeloablative syndrome linked to high medullary damage for a dose range higher than 68 Gy, resulting in very late or no recovery. Prognosis will depend on the presence or absence of radio-combined injuries, the toxicity of the transplant procedure, and the risk of rejection induced by insufficient percritical immunosuppression. It is in this context that new cell therapy modalities, which combine enhanced peripheral hematopoietic cell engraftment and high immunosuppressive conditioning regimen with low extrahematological toxicity, inducing early and stable mixed lymphomyeloid chimerism with minimal morbidity, can be considered. Such an approach is being evaluated in the treatment of patients with hematological malignancies at high risk of transplant-related mortality using conventional bone marrow methods. Key words: medullary aplasia, irradiation, hematopoiesis, bone marrow, grafting.[Journal translation]

Style APA, Harvard, Vancouver, ISO itp.

6

Pierre, S., M. Heiblig, M. Nourredine, K. Bihan, C. Le Souder, P. Sanchez-Pena, F. Perrouin, G. Grenet i T. Vial. "Traitement antidotique par glucarpidase dans l’insuffisance rénale aiguë secondaire au méthotrexate haute-dose : y a-t-il un bénéfice clinique ?" Toxicologie Analytique et Clinique 35, nr 3 (październik 2023): S88. http://dx.doi.org/10.1016/j.toxac.2023.08.041.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

7

Trojan i Borelli. "Chemotherapie-Nebenwirkungen an Haut und Schleimhäuten". Praxis 91, nr 24 (1.06.2002): 1078–87. http://dx.doi.org/10.1024/0369-8394.91.24.1078.

Pełny tekst źródła

Streszczenie:

Des effets indésirables de la chimiothérapie se manifestent souvent sur la peau. L'alopécie et la stomatite sont les plus fréquents. En particulier les réactions des muqueuses peuvent limiter la dose ou en cas d'infection secondaire mettre le patient en danger. Des changements des ongles ou des hyperpigmentations sont des problèmes cosmétiques. Pour le diagnostic des maladies spécifiques comme le syndrome acral d'erythrodysesthésie ou l'hidradénite eccrine neutrophile, la connaissance de l'image clinique est nécessaire. Des interactions avec la radiothérapie ou la lumière UV peuvent aggraver ou faire apparaître des réactions sur la peau. On peut observer également des réactions semblables avec des nouvelles substances ayant des mécanismes tout à fait différents et des thérapeutiques immunitaires comme les anticorps monoclonaux.

Style APA, Harvard, Vancouver, ISO itp.

8

Pichard, Diane. "Les polyarthrites du chien". Le Nouveau Praticien Vétérinaire canine & féline 19 (grudzień 2022): 40–49. http://dx.doi.org/10.1051/npvcafe/2023008.

Pełny tekst źródła

Streszczenie:

Les polyarthrites du chien sont un ensemble de maladies inflammatoires affectant plusieurs articulations simultanément, à l’origine de répercussions systémiques peu spécifiques, telles qu’une hyperthermie, un abattement, une léthargie, mais aussi spécifiques telles que des troubles locomoteurs et une polyarthralgie plus ou moins sévère. Les polyarthrites canines revêtent de nombreuses causes différentes. L’examen complémentaire de choix permettant de confirmer le diagnostic d’inflammation articulaire est l’arthrocentèse et au moins 4 articulations doivent ainsi être prélevées. Des arguments paracliniques peuvent étayer l’orientation étiologique. La caractérisation de l’atteinte d’un point de vue cytologique et bactériologique permet de distinguer une origine inflammatoire stricte (par dépôts d’immuns complexes d’origine primaire ou secondaire à un foyer inflammatoire à distance des articulations) d’une origine infectieuse. La polyarthrite à médiation immune primaire est la principale affection au sein des polyarthrites du chien. Elle est considérée idiopathique et il s’agit d’un diagnostic d’exclusion. La recherche de la cause doit être systématique afin de mettre en place le traitement adapté. Une polyarthrite d’origine infectieuse est traitée par l’administration d’un anti-infectieux adapté. La gestion d’une polyarthrite à médiation immune primaire repose sur une corticothérapie souvent de longue durée et dont la dégression de dose doit être surveillée de façon rapprochée. La prise en charge d’une polyarthrite à médiation immune secondaire invite à la prise en charge de la cause sous-jacente quand cela est possible.

Style APA, Harvard, Vancouver, ISO itp.

9

Shayeb, H., T. Riabit, M. Roustan i A. Hassan. "Étude expérimentale et modélisation de la désinfection par le chlore des eaux usées épurées". Revue des sciences de l'eau 11, nr 4 (12.04.2005): 517–36. http://dx.doi.org/10.7202/705319ar.

Pełny tekst źródła

Streszczenie:

Pour étudier la désinfection d'une eau usée épurée au stade secondaire, traitée à l'hypochlorite de sodium, des essais en réacteur fermé ont été effectués en utilisant des doses variant entre 1 et 10 mg de chlore par litre. Les résultats obtenus montrent que la cinétique de désinfection est loin d'être uniforme. L'utilisation du modèle de Chick et Watson n'est en effet possible que si on l'adapte pour tenir compte de la modification de la vitesse de désinfection au cours du processus. Le modèle de Collins et Selleck permet de rendre compte de façon satisfaisante de l'évolution de la vitesse d'élimination des germes au cours du temps. La faible valeur du paramètre t trouvée (0.26 min.mg/l pour les coliformes totaux et 0.58 min.mg/l pour les coliformes fécaux) semble cependant démontrer que la période de latence est relativement peut importante surtout lorsqu'on utilise des dose de chlore élevées. Il s'avère d'autre part que la demande en chlore de ce type d'eau est très importante. La concentration en chlore résiduel dans le réacteur décroît très rapidement pour atteindre environs 10 % de la dose de chlore injectée et cela quelle que soit la dose utilisée (de 1 à 10 mg/l). Le dimensionnement des réacteurs de désinfection fonctionnant en continu nécessite de prendre en compte le comportement hydrodynamique de l'eau dans le réacteur. Sachant qu'un abattement de 3 U-Log est nécessaire, dans le cas de la réutilisation de l'eau pour l'irrigation, un modèle intégrant l'expression de la cinétique de désinfection et l'hydrodynamique du contacteur a été proposé. Les résultats mettent en évidence l'intérêt de concevoir des réacteurs se rapprochant le plus possible de l'écoulement piston.

Style APA, Harvard, Vancouver, ISO itp.

10

Savary, B., R. Levilly, A. Laplanche, D. Wolbert i M. Lemasle. "Formation des ions bromate dans une colonne à bulles: Effets du peroxyde d'hydrogène lors de l'ozonation". Revue des sciences de l'eau 13, nr 2 (12.04.2005): 139–54. http://dx.doi.org/10.7202/705386ar.

Pełny tekst źródła

Streszczenie:

L'utilisation de l'ozone, aujourd'hui très répandue dans les filières de potabilisation, n'est pas sans effet secondaire. De nombreux sous-produits peuvent se former comme notamment les ions bromates, sous produits finaux d'oxydation des bromures contenus dans les eaux. Malheureusement, le mécanisme de production de cette espèce est complexe et dépend de nombreux paramètres difficiles à appréhender. Sur une installation pilote de type colonne à bulles fonctionnant à contre-courant, nous avons étudié l'influence de différents paramètres, comme le pH, le temps de contact, la dose d'ozone et la dose de peroxyde d'hydrogène, sur la formation des bromates et la dégradation des pesticides, représentée par l'atrazine. Les résultats de la littérature ont été confirmés lors de l'emploi unique de l'ozone. La formation des ions bromate est influencée par la présence du peroxyde d'hydrogène. Cet oxydant intervient de manière non négligeable sur la consommation des entités intermédiaires. Le couple HOBr/OBr- peut être oxydé par l'ozone moléculaire et le radical OH° mais peut également être réduit par l'ozone et par le peroxyde sous sa forme acide ou sa base conjuguée. En ce qui concerne la dégradation des pesticides, l'utilisation de peroxyde d'hydrogène couplé à l'ozone favorise l'oxydation de la molécule d'atrazine grâce à la présence plus importante de radicaux hydroxyles. Une pollution accidentelle en pesticides pourra être traitée par l'ajout ponctuel de peroxyde d'hydrogène avec une augmentation de pH, la formation des bromates sera, dans ce cas, faible. La désinfection sera alors assurée par l'étape de chloration.

Style APA, Harvard, Vancouver, ISO itp.

11

Akassimadou, Fulgence E., Marie P. Hien, Felix B. Bouadou Oi, Emile B. Bolou Bi, Jeanne A. Bongoua, Jean-Baptiste D. Ettien i Albert Yao-kouame. "Efficiences Des Nutriments P Et K En Riziculture Irriguée Dans Un Bas-Fond Secondaire En Zone De Savane Guinéenne De La Côte d’Ivoire". European Scientific Journal, ESJ 13, nr 36 (31.12.2017): 432. http://dx.doi.org/10.19044/esj.2017.v13n36p432.

Pełny tekst źródła

Streszczenie:

N-nitrogen is the most limiting element in rice-growing on lowland soils in the central part of Côte d'Ivoire. In addition to its direct effect, poor management of P and K fertilizers in basic manure can induce low yields and losses of currencies. However, inappropriate use of these nutrients (P and K) in these shallows can induce other adverse effects on crops and even on the environment. So, for the eficient management of lowland ricegrowing fertiliszation, three agronomic trials have been set up in the Central part of Côte d'Ivoire to determine the optimum P and K doses to improve fertilizer efficiency in the relevant agroecology. Three rates of PCa(H2PO4)2H2O [30, 60 and 90 kgPha-1 ] as well as three of K-KCl [25, 50 and 75kgKha-1 ] and their recommended rates (13kgPha-1 and 25kgKha-1 ) in the humid forest zone were the treatments. A total of 80kgNha-1 (urea) was applied in three splits to each of the micro-plots except in the control including no fertilizer. The rice variety named NERICA L19 was transplanted.An agronomic trial including eleven (11) treatments in three replications was laid out in a complete randomized blocks design The highest K recovery rate is obtained with the 25kgKha -1 rates, while the lowest rate is with 50kgKha-1 in the three trials. There is a gradual decrease in P-level recovery as rates increase, regardless of the test. Increased rates of P and K induce a decrease in agronomic efficiency. The partial productivity factor (PFP) of nutrients P and K decreases with increasing rates for all three trials. The highest grains and straw yields are obtained for 75kgKha-1 doses regardless of the dose of P. However, it should be noted that the different efficiencies obtained are better for the lower rates of P and K

Style APA, Harvard, Vancouver, ISO itp.

12

Philippot, Q., A. Roche, C. Goyard, J. Pastré, B. Planquette, G. Meyer i O. Sanchez. "Prise en charge de l'embolie pulmonaire grave en réanimation". Médecine Intensive Réanimation 27, nr 5 (6.06.2018): 443–51. http://dx.doi.org/10.3166/rea-2018-0037.

Pełny tekst źródła

Streszczenie:

L'embolie pulmonaire (EP) grave, définie par la présence d’un état de choc, est à l'origine d'une mortalité importante. L'objectif de cette mise au point est de synthétiser les dernières avancées et recommandations concernant la prise en charge des formes graves d'EP. La stratification du risque individuel de mortalité précoce permet d'apporter une stratégie diagnostique et thérapeutique optimisée pour chaque patient. Le traitement symptomatique consiste essentiellement en la prise en charge de l'état de choc. L'anticoagulation curative par héparine non fractionnée est réservée aux patients hémodynamiquement instables. Chez ces patients à haut risque, la thrombolyse systémique diminue la mortalité et le risque de récidive d'EP. Chez les patients à risque intermédiaire élevé, la thrombolyse systémique à dose standard diminue le risque de choc secondaire mais sans impact sur la mortalité globale. La thrombolyse est donc réservée aux patients à risque intermédiaire élevé présentant secondairement un état de choc. L'embolectomie chirurgicale reste indiquée en cas de contre-indication absolue à la thrombolyse ou en cas d'échec de celle-ci. Le positionnement dans l'algorithme thérapeutique de l'assistance extracorporelle et des techniques percutanées de revascularisation reste à définir. Leurs indications doivent donc être discutées dans des centres experts après une concertation multidisciplinaire incluant pneumologues, cardiologues, réanimateurs, radiologues interventionnels et chirurgiens cardiaques.

Style APA, Harvard, Vancouver, ISO itp.

13

Togo, Sara, Diakalia Sogodogo, Joseph Sékou B. Dembele i Sidiki Gabriel Dembele. "Effet de la fertilisation organo-minérale sur le rendement du sorgho dans la zone Soudano-Sahélienne du Mali". International Journal of Biological and Chemical Sciences 17, nr 5 (29.10.2023): 1841–55. http://dx.doi.org/10.4314/ijbcs.v17i5.6.

Pełny tekst źródła

Streszczenie:

Le sorgho constitue l’alimentation de bases des millions de population vivant dans les milieux ruraux en Afrique. Malgré son importance, le rendement du sorgho est faible avec moins d’une tonne à l’hectare dû à la variation climatique et à la faible fertilité des sols. La réponse des variétés à la fertilisation minérale et organique peut booster la production du sorgho au Mali. L’objectif de cette étude était de déterminer la réponse de trois variétés de sorgho à la combinaison de fertilisation minérale et organique (Sabunyuma (Sab)) en rendement grain dans la zone soudano-sahélienne du Mali. Pour atteindre cet objectif, un essai a été conduit consécutivement en 2017, 2018 et 2019 à la station expérimentale de Cinzana. Les variétés de sorgho constituaient le facteur principal et la fertilisation composée de neuf doses étaient le facteur secondaire. Les doses de fertilisation étaient : D1 (sans engrais), D2 (0 kg/ha de DAP + 3000 kg/ha de Sab), D3 (0 kg/ha de DAP + 6000 kg/ha de Sab), D4 (30 kg/ha de DAP + 0 kg/ha de Sab), D5 (30 kg/ha de DAP + 3000 kg/ha de Sab), D6 (30 kg/ha de DAP + 6000 kg/ha de Sab), D7 (60 kg/ha de DAP + 0 kg/ha de Sab), D8 (60 kg/ha de DAP + 3000 kg/ha de Sab) et D9 (60 kg/ha de DAP + 6000 kg/ha de Sab). Les résultats ont montré que la variété Tiandougoucoura a produit les meilleurs rendements grain et paille, poids des panicules et nombre de grain par panicule, et la variété Jakunbe précoce a produit le nombre de panicules et poids 1000 grains les plus élevés. L’application de D9 a augmenté les rendements grain et paille, poids des panicules, poids 1000 grains, nombre de panicules par m² et le raccourcissement de la durée de floraison. La variété Tiandougoucoura a produit les meilleurs rendements grain et paille avec l’application de la dose D9. Sous l’application de la dose D9 par microdosage, la variété Tiandougoucoura peut être recommandée pour assurer une plus grande productivité de sorgho dans les différentes zones de culture. Sorghum constitutes the staple food for millions of people living in rural areas in Africa. Despite its importance, sorghum yields are low with less than one ton per hectare due to climatic variation and low soil fertility. The response of varieties to mineral and organic fertilization can boost sorghum production in Mali.The objective of this study was to determine the response of three sorghum varieties to the combination of mineral and organic fertilization (Sabunyuma (Sab)) in grain yield in the Soudano-Sahelian zone of Mali. To achieve this objective, a trial was conducted consecutively in 2017, 2018 and 2019 at the experimental station of Cinzana. Sorghum varieties were the main factor and nine-dose fertilization was the secondary factor. Fertilization doses were: D1 (no fertilization), D2 (0 kg/ha DAP + 3000 kg/ha Sab), D3 (0 kg/ha DAP + 6000 kg/ha Sab), D4 (30 kg/ha DAP + 0 kg/ha Sab), D5 (30 kg/ha DAP + 3000 kg/ha Sab), D6 (30 kg/ha DAP + 6000 kg/ha Sab), D7 (60 kg/ha DAP + 0 kg/ha Sab), D8 (60 kg/ha DAP + 3000 kg/ha Sab) and D9 (60 kg/ha DAP + 6000 kg/ha Sab). The results showed that Tiandougoucoura variety produced the best grain and straw yields, panicle weight and number of grains per panicle and early Jakunbe variety produced the highest number of panicles and 1000 grains weight. The application of D9 increased grain and straw yields, panicle weight, 1000 grain weight, number of panicles per m² and shortened flowering time. The Tiandougoucoura variety produced the best grain and straw yields with the application of the D9 dose. Under the application of the D9 dose by microdosing, the Tiandougoucoura variety can be recommended to ensure greater productivity of sorghum in the different cultivation areas.

Style APA, Harvard, Vancouver, ISO itp.

14

Ravi, K., S. Sweetser i D. A. Katzka. "Pseudoachalasia secondary to bariatric surgery". Diseases of the Esophagus 29, nr 8 (10.09.2015): 992–95. http://dx.doi.org/10.1111/dote.12422.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

15

Schmutz, J. L. "Cytopénies secondaires au méthotrexate à faible dose". Annales de Dermatologie et de Vénéréologie 147, nr 3 (marzec 2020): 252–53. http://dx.doi.org/10.1016/j.annder.2020.01.001.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

16

Schulman, Sam. "Anticoagulation in venous Thrombosis". Journal of the Royal Society of Medicine 89, nr 11 (listopad 1996): 624–30. http://dx.doi.org/10.1177/014107689608901108.

Pełny tekst źródła

Streszczenie:

Major studies addressing various aspects of the treatment of deep vein thrombosis are reviewed. It has lately been demonstrated that heparin should be dosed according to body weight and is preferably given as subcutaneous injections twice daily. Alternatively, low-molecular-weight heparins may be given in a fixed dose once daily, which does not require monitoring. Oral anticoagulation should be started concomitantly with heparin and targeted at an international normalized ratio of 2.0-3.0. This treatment should continue for a longer duration than previously accepted, in many cases for 6 months. For patients with contraindications to oral anticoagulation, secondary prophylaxis with a low-molecular-weight heparin is also effective and safe.

Style APA, Harvard, Vancouver, ISO itp.

17

Walker, R. W., J. C. Allen, G. Rosen i B. Caparros. "Transient cerebral dysfunction secondary to high-dose methotrexate." Journal of Clinical Oncology 4, nr 12 (grudzień 1986): 1845–50. http://dx.doi.org/10.1200/jco.1986.4.12.1845.

Pełny tekst źródła

Streszczenie:

A transient acute neurologic syndrome occurred in 22 patients receiving high-dose methotrexate (HDMTX) (8 to 9 g/m2) for a variety of malignancies. The neurologic signs were similar in all cases. The syndrome occurred an average of six days after the second or third weekly treatment. Common findings included behavioral abnormalities, focal sensorimotor signs, and abnormal reflexes. Signs often alternated from one side to the other. Evaluations including computed tomography (CT) scan, lumbar puncture, hemogram, and blood chemistry were normal. The EEG revealed some slowing in all cases. The cause of this syndrome is unknown. It is transient and usually does not recur. Its appearance does not preclude further treatment with HDMTX.

Style APA, Harvard, Vancouver, ISO itp.

18

Segalin, A., L. Bonavina, A. Ruol, P. Boccasanta, G. Salamina i A. Peracchia. "Secondary esophageal tumors: treatment and outcome in 115 consecutive patients". Diseases of the Esophagus 7, nr 2 (1.01.1994): 118–21. http://dx.doi.org/10.1093/dote/7.2.118.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

19

Wiseman, Alexander W. "Representations of Islam and Arab Societies in Western Secondary Textbooks". Digest of Middle East Studies 23, nr 2 (wrzesień 2014): 312–44. http://dx.doi.org/10.1111/dome.12047.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

20

Al-Basheer, A., G. Sjoden i M. Ghita. "SU-FF-T-619: Electron Dose Kernels to Account For Secondary Particle Doses in Deterministic Simulations". Medical Physics 36, nr 6Part18 (czerwiec 2009): 2667. http://dx.doi.org/10.1118/1.3182117.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

21

Luke, Jason J., Anthony J. Olszanski, Igor Puzanov, Dan Lu, Adrian Hackett, Stella Martomo, Jeegar Patel i in. "Phase I dose escalation of KD033, a PDL1-IL15 bispecific molecule, in advanced solid tumors." Journal of Clinical Oncology 39, nr 15_suppl (20.05.2021): 2568. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.2568.

Pełny tekst źródła

Streszczenie:

2568 Background: IL-2 and IL-15 signal through the shared IL-2/15 βγ receptor, but unlike IL-2, IL-15 does not expand regulatory T cells (Tregs), does not mediate activation-induced cell death and may have an improved therapeutic index. KD033 is a fusion antibody combining a fully human, high affinity anti-human Programmed Death Ligand 1 (PD-L1) IgG1 antibody with the human IL-15 receptor alpha (IL15Rα) sushi domain and human IL-15 (IL-15). KD033 (or its mouse cross reactive surrogate molecule, srKD033) has been extensively characterized in multiple in vitro and in vivo nonclinical studies. The fusion of anti-PD-L1 antibody to IL-15 significantly increases the maximal-tolerated dose (MTD) of srKD033 in mice compared to free IL-15. In addition, srKD033 has exhibited increased efficacy in rejecting tumors in mice as compared to the combination of its individual components, anti-PD-L1 antibody and IL-15. Methods: This is a phase 1, open-label, multiple ascending dose, multi-center clinical trial being conducted in patients with metastatic or locally advanced solid tumors (NCT04242147). The primary objective is to determine the safety and tolerability and the MTD of KD033. Secondary objectives include characterization of PK and immunogenicity, evaluation of CD8 T and NK cell activation and assessment of best overall response and duration of response. KD033 is administered by IV infusion over 30 minutes every 14 days. Accelerated intra-patient dose escalation across the initial three dose levels, followed by 3+3 escalation thereafter, is investigating dose ranges from 3 µg/kg to 600 µg/kg. Efficacy evaluation is planned in an expansion cohort of patients with PD-1/L1 refractory tumors. Results: A total of 7 patients have received treatment. Three patients were dosed in Cohort 1 and four patients were dosed in Cohort 2. Through two dose escalation cohorts (3 µg/kg – 25 µg/kg), no dose-limiting toxicities have been reported. Grade 1-2 treatment-related toxicities, when observed, resolved within 24 hours with supportive management. 6 patients are evaluable for treatment response with one patient (adenoid cystic carcinoma) in the first cohort having stable disease for more than 6 months. Conclusions: KD033 has been well tolerated early in dose escalation with on-mechanism pharmacodynamics consistent with IL-15 agonism. Clinical trial information: NCT04242147.

Style APA, Harvard, Vancouver, ISO itp.

22

Kotsis, L., K. Zubovits i Z. Heiler. "Particular aspects and limits of palliation of secondary malignant esophageal strictures". Diseases of the Esophagus 10, nr 4 (1.10.1997): 238–42. http://dx.doi.org/10.1093/dote/10.4.238.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

23

Hadacek, Franz, Gert Bachmann, Doris Engelmeier i Vladimir Chobot. "Hormesis and a Chemical Raison D'ětre for Secondary Plant Metabolites". Dose-Response 9, nr 1 (23.04.2010): dose—response.0. http://dx.doi.org/10.2203/dose-response.09-028.hadacek.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

24

Fatmayanti, Halinda, Dwi Rochmayanti, Ade Irma Handayani, Andrey Nino Kurniawan i Yeti Kartikasari. "Profil Dosis Sekunder Ct Scan Sinus Paranasal Dengan Aplikasi Software Organ Dose Modulation (ODM)". JRI (Jurnal Radiografer Indonesia) 7, nr 1 (31.05.2024): 52–57. http://dx.doi.org/10.55451/jri.v7i1.284.

Pełny tekst źródła

Streszczenie:

Background: A radiological examination that can be used to evaluate SPN and facial bones is CT SPN. CT SPN increases the potential risk of radiation effects, especially on sensitive organs (thyroid and mammae). CT SPN exposure does not only affect the main organs but also the surrounding organs (secondary doses). The secondary dose also increases the risk of stochastic effects. Unfortunately, secondary doses are rarely measured. So, there is a need for safety and radiation protection like using Organ Dose Modulation (ODM) software. The purpose of this study was To determine the secondary dose in CT SPN using ODM software. Methods: This research is quantitative research with an experimental study approach carried out in March–May 2023 at the Radiology Installation of Indriati Solo Baru Hospital. This research was carried out by scanning the phantom with standard CT SPN protocol and adding ODM software, then measuring the dose using TLD BARC which was placed on the thyroid and mammae area. The results of the absorbed dose in thyroid and mammae were analyzed descriptively and analytically. Result: The mean absorbed dose value in the thyroid gland area without ODM software was 9.44 mSv and with ODM software was 5.12 mSv. In the breast area without ODM software, the mean absorbed dose value was 0.85 mSv, while using ODM software was 0.59 mSv. The decreased absorbed dose using ODM software in the thyroid is 44,57% and in the breast is 29,85%. Conclusion: Using ODM software in CT SPN can reduce the secondary dose (thyroid and breast areas)

Style APA, Harvard, Vancouver, ISO itp.

25

Klassen, Tara D., Sean P. Dukelow, Mark T. Bayley, Oscar Benavente, Michael D. Hill, Andrei Krassioukov, Teresa Liu-Ambrose i in. "Higher Doses Improve Walking Recovery During Stroke Inpatient Rehabilitation". Stroke 51, nr 9 (wrzesień 2020): 2639–48. http://dx.doi.org/10.1161/strokeaha.120.029245.

Pełny tekst źródła

Streszczenie:

Background and Purpose: We investigated the effect of higher therapeutic exercise doses on walking during inpatient rehabilitation, typically commencing 1 to 4 weeks poststroke. Methods: This phase II, blinded-assessor, randomized controlled trial recruited from 6 Canadian inpatient rehabilitation units, between 2014 and 2018. Subjects (n=75; 25/group) were randomized into: control (usual care) physical therapy: typically, 1 hour, 5 days/week; Determining Optimal Post-Stroke Exercise (DOSE1): 1 hour, 5 days/week, more than double the intensity of Control (based on aerobic minutes and walking steps); and DOSE2: 2 hours, 5 days/week, more than quadruple the intensity of Control, each for 4 weeks duration. The primary outcome, walking endurance at completion of the 4-week intervention (post-evaluation), was compared across these groups using linear regression. Secondary outcomes at post-evaluation, and longitudinal outcomes at 6 and 12-month evaluations, were also analyzed. Results: Both DOSE1 (mean change 61 m [95% CI, 9–113], P =0.02) and DOSE2 (mean change 58 m, 6–110, P =0.03) demonstrated greater walking endurance compared with Control at the post-evaluation. Significant improvements were also observed with DOSE2 in gait speed (5-m walk), and both DOSE groups in quality of life (EQ-5D-5 L) compared with Control. Longitudinal analyses revealed that improvements in walking endurance from the DOSE intervention were retained during the 1-year follow-up period over usual care. Conclusions: This study provides the first preliminary evidence that patients with stroke can improve their walking recovery and quality of life with higher doses of aerobic and stepping activity within a critical time period for neurological recovery. Furthermore, walking endurance benefits achieved from a 4-week intervention are retained over the first-year poststroke. Registration: URL: https://www.clinicaltrials.gov . Unique identifier: NCT01915368.

Style APA, Harvard, Vancouver, ISO itp.

26

Anonymous. "Low-Dose Aspirin Can Prevent Secondary Stroke". Journal of Gerontological Nursing 25, nr 11 (listopad 1999): 3. http://dx.doi.org/10.3928/0098-9134-19991101-04.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

27

&NA;. "LOW-DOSE ASPIRIN FOR SECONDARY STROKE PREVENTION". American Journal of Nursing 99, nr 3 (marzec 1999): 24DD. http://dx.doi.org/10.1097/00000446-199903000-00021.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

28

Kumar, P., C. Watts, T. Svimonishvili, M. Gilmore i E. Schamiloglu. "The Dose Effect in Secondary Electron Emission". IEEE Transactions on Plasma Science 37, nr 8 (sierpień 2009): 1537–51. http://dx.doi.org/10.1109/tps.2009.2022970.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

29

Lyng, H., i E. K. Rofstad. "Thermal dose and secondary tumour cell death". International Journal of Hyperthermia 9, nr 5 (styczeń 1993): 755–61. http://dx.doi.org/10.3109/02656739309032062.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

30

Jaffe, N. "Cerebral dysfunction secondary to high-dose methotrexate." Journal of Clinical Oncology 5, nr 4 (kwiecień 1987): 681–82. http://dx.doi.org/10.1200/jco.1987.5.4.681.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

31

Janiszewska, M., B. Karaczyn, K. Polaczek Grelik i A. Konefał. "Secondary Radiation Dose during High-energy TBI". International Journal of Radiation Oncology*Biology*Physics 78, nr 3 (listopad 2010): S637. http://dx.doi.org/10.1016/j.ijrobp.2010.07.1483.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

32

Fahimian, Benjamin P., John J. DeMarco, Roy Keyes, Niels Bassler, Keisuke S. Iwamoto, Maria Zankl i Michael H. Holzscheiter. "Antiproton radiotherapy: peripheral dose from secondary neutrons". Hyperfine Interactions 194, nr 1-3 (29.08.2009): 313–18. http://dx.doi.org/10.1007/s10751-009-0086-6.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

33

Ramírez-Alvarado, Rafael Andrés, Aníbal Orlando Herrera-Arévalo, Yamid Ortiz-Rojas i Claudia Patricia Pérez-Rodríguez. "Impact of ultraviolet B radiation applications on some secondary metabolites in thyme (Thymus vulgaris L.)". Revista Colombiana de Ciencias Hortícolas 14, nr 3 (1.09.2020): 416–23. http://dx.doi.org/10.17584/rcch.2020v14i3.12082.

Pełny tekst źródła

Streszczenie:

The impact of ultraviolet radiation B (UV-B) applications on the production of secondary metabolites, such as phenols, flavonoids and anthocyanins, in thyme plants was studied. The stems, leaves and flowers were subjected to an experiment design that had a 4´2 factorial arrangement, evaluating: dose UV-B radiation (0.05 and 0.075 Wh m-2), sampling points (75 days after transplanting [cut-off point] and 92 days after transplanting [full flowering] according to the BBCH scale), adaptation time (24 and 49 hours) and extraction matrices of plant material (fresh and dried). The experiment unit corresponded to matrices from Thymus vulgaris L. (C.N. thyme) plants. Ten extractions were done per treatment, and a chemical analysis test were performed in triplicate. The extraction was done with a modified Randall method. The results showed that the application of UV-B radiation at a dose of 0.075 Wh m-2 increased the concentration of secondary metabolites of interest. The compounds that showed a better response to treatment were phenols and anthocyanins.

Style APA, Harvard, Vancouver, ISO itp.

34

Hilley, P., A. R. Peterson, D. Wong, K. Hine, A. Srinivasan, M. C. Choy i P. De Cruz. "P594 Vedolizumab dose intensification does not always improve treatment persistence". Journal of Crohn's and Colitis 16, Supplement_1 (1.01.2022): i530. http://dx.doi.org/10.1093/ecco-jcc/jjab232.720.

Pełny tekst źródła

Streszczenie:

Abstract Background Vedolizumab is effective in inducing and maintaining remission in patients with both Crohn’s Disease (CD) and ulcerative colitis (UC). Recent data has demonstrated that there is superior persistence with vedolizumab compared to anti-TNF biologics. However, the efficacy of dose intensified vedolizumab remains uncertain. We aimed to assess whether vedolizumab dose intensification resulted in a meaningful improvement in treatment persistence and to determine whether there were any clinical, biochemical or endoscopic parameters that were associated with a response to dose intensification. Methods A retrospective analysis of all patients with CD or UC that had received dose intensified vedolizumab every 4 weeks, was undertaken at an Australian tertiary, metropolitan IBD service between the 1st of July 2015 and 15th of November 2021. Electronic medical records were reviewed to retrospectively calculate the partial Mayo score (pMS) for UC and Harvey-Bradshaw Index (HBI) for CD, as well as document the C-Reactive Protein (CRP), Faecal Calprotectin (FC) and endoscopic disease assessment. Data were obtained at commencement of vedolizumab, time of dose escalation, as well as at 6 and 12 months post escalation. The primary outcome was treatment persistence at 6 months post escalation. Results A total of 33 patients required dose intensification to address primary non-response or secondary loss of response. Median time to escalation was 9 months (IQR 3–14). 11/33 (33%) remained on escalated dosing at the end of the study period. 4/11 (36%) were escalated prior to, and 7/11(32%) after week 14. Escalated therapy was continued for a median of 5 months (IQR 3–12). Treatment persistence was 45% at 6 months, and 24% at 12 months. In patients who had vedolizumab ceased at 6 months post escalation, there was a rate of clinical activity of 93%, biochemical activity of 93% and endoscopic activity of 100%. For those maintained on vedolizumab at 6 months post intensification the rates were 50% for both clinical and biochemical activity. No clinical/biochemical/endoscopic parameters were associated with response and no statistically significant difference was noted in disease activity following escalation. Conclusion There was a low rate of treatment persistence for patients undergoing vedolizumab dose intensification. Rates of disease activity at the time of cessation for patients who discontinued vedolizumab were high. Dose intensification of vedolizumab may not capture response nor translate into treatment persistence. Further prospective studies examining vedolizumab levels and dose intensification are warranted but these data suggest a low threshold for switching to alternative agents if response cannot be captured within 6 months of dose escalation.

Style APA, Harvard, Vancouver, ISO itp.

35

Sannarangappa, Vishnu, i Ryan Jalleh. "Inhaled Corticosteroids and Secondary Adrenal Insufficiency". Open Respiratory Medicine Journal 8, nr 1 (31.12.2014): 93–100. http://dx.doi.org/10.2174/1874306401408010093.

Pełny tekst źródła

Streszczenie:

Inhaled corticosteroids (ICS) have been used as first line treatment of asthma for many decades. ICS are a form of exogenous glucocorticosteroids that can suppress the endogenous production of glucocorticosteroids, a condition known as adrenal suppression (AS). As a result, cessation, decreasing the dose or changing the type of ICS may trigger features of adrenal insufficiency (AI). AI may cause a spectrum of presentations varying from vague symptoms of fatigue to potentially life threatening acute adrenal crises. This article reviews the current literature on ICS and AI particularly in adults (although majority of data available is from the paediatric population). It aims to increase awareness of the potential risk of AI associated with ICS use, delineate the pathogenesis of AI and to provide recommendations on screening and management. From our literature review, we have found numerous case reports that have shown an association between ICS and AI particularly in children and patients using high doses. However, there have also been reports of AI in adults as well as in patients using low to moderate doses of ICS. To conclude, we recommend screening for AI in select patient groups with an initial early morning serum cortisol. If results are abnormal, more definitive testing such as the low dose corticotropin stimulation test may be done to confirm the diagnosis.

Style APA, Harvard, Vancouver, ISO itp.

36

Adcock, Kim G., Dawn E. MacElroy, Eric T. Wolford i Elizabeth A. Farrington. "Pemoline Therapy Resulting in Liver Transplantation". Annals of Pharmacotherapy 32, nr 4 (kwiecień 1998): 422–25. http://dx.doi.org/10.1345/aph.17279.

Pełny tekst źródła

Streszczenie:

OBJECTIVE: To describe a case of pemoline-induced liver failure resulting in liver transplantation. CASE SUMMARY: A 9-year-old white boy, diagnosed with attention deficit/hyperactivity disorder (ADHD) and treated with pemoline, developed signs and symptoms of liver failure. Pemoline therapy was discontinued, but the patient's liver function continued to decline. Ultimately, a liver transplantation was required. DISCUSSION: Pemoline, an agent used in ADHD treatment, has been associated with hepatotoxicity with the majority of cases occurring in pediatric patients. To our knowledge, this is the second reported case of pemoline-induced liver failure resulting in liver transplantation. The mechanism of action remains unclear, with several hypotheses being postulated including hypersensitivity reactions, dose-related phenomena, and autoimmune-mediated reactions. CONCLUSIONS: With increasing evidence linking pemoline to liver failure, this agent should not be considered first-line therapy for ADHD. Prior to initiating therapy, baseline liver function tests should be obtained and closely monitored, and parents and patients should be educated on the signs and symptoms of liver toxicity. OBJETIVO: Reportar un caso de fallo hepático inducido por pemoline que resultó en el requerimiento de un transplante del hígado. RESUMEN DEL CASO: Un niño de 9 años de edad, que fue diagnosticado con la deficit de atención e hiperactividad y tratado con pemoline, desarrolló signos y síntomas consistentes con el fallo de hígado. Se descontinuó la terapia con pemoline, pero la función hepática del paciente continuó a deteriorarse. El paciente últimamente necesitó un transplante del hígado. DISCUSSIÓN: Pemoline, un agente usado en el tratamiento de la deficit de atención e hiperactividad, ha sido asociado con el desarrollo de hepatotoxicidad. La mayoría de estos casos han ocurrido en pacientes pediátricos. Que nosotros sepamos, este es el segundo reportado caso de fallo hepático inducido por pemoline que resultó en un transplante del hígado. Se desconce todavía el mecanismo de acción de este efecto adverso pero se han postulado varias hipótesis incluyendo reacciónes de hipersensibilidad, fenómenos relacionados a la dosis, y reacciónes autoinmunes. CONCLUSIONES: Dado la creciente evidencia conectando pemoline al desarrollo de fallo del hígado, no se debe considerar este agente como primera linea en el tratamiento de la deficit de atención e hiperactividad. Se debe conseguir pruebas de funciónes hepáticas antes de iniciar el medicamento y éstas deben ser cuidadosamente evaluadas durante la terapia. Además, se sugiere que los padres y pacientes sean orientados acerca de los signos y síntomas de toxicidades del hígado associado con este medicamento. OBJECTIF: Rapporter un cas d'insuffisance hépatique secondaire à la pémoline et résultant en une transplantation hépatique. RÉSUMÉ DU CAS: Un enfant mâle de 9 ans diagnostiqué avec un désordre d'hyperactivité et traité à la pémoline a développé des signes et symptômes d'insuffisance hépatique. Malgré la thérapie discontinuee, la fonction hépatique du patient s'est détériorée au point où il nécessita une transplantation hépatique. DISCUSSION: La pémoline, un agent utilisé dans le traitement du syndrome d'hyperactivité, a été associee à de l'hépatotoxicité surtout chez des patients pédiatriques. À notre connaissance, ce cas constitue le second rapport d'hépatotoxicité nécessitant une transplantation. Le mécanisme d'action demeure incertain; une réaction d'hypersensibilité, un phénomène relié à la dose ou une réaction immunitaire ont été avancés comme hypothèse. CONCLUSIONS: En présence de l'évidence liant l'insuffisance hépatique et la pémoline, ce dernier ne doit pas être considéré comme agent de première ligne. Avant de début de la thérapie, il est recommandé d'obtenir les tests de fonction hépatique et par la suite, d'effectuer un suivi étroit ainsi que d'éduquer les patients et leurs parents sur les signes et symptômes d'hépatotoxicité.

Style APA, Harvard, Vancouver, ISO itp.

37

Jian, Hu, Gong Ming, Song Shuai, Wang Tianyou i Chang Dong. "Case report of achalasia secondary to a lung carcinoma of the mediastinal type". Diseases of the Esophagus 29, nr 7 (1.04.2015): 891–93. http://dx.doi.org/10.1111/dote.12313.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

38

Dzierma, Yvonne, Peter Minko, Franziska Ziegenhain, Katharina Bell, Arno Buecker, Christian Rübe i Philippe Jagoda. "Abdominal imaging dose in radiology and radiotherapy – Phantom point dose measurements, effective dose and secondary cancer risk". Physica Medica 43 (listopad 2017): 49–56. http://dx.doi.org/10.1016/j.ejmp.2017.10.019.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

39

Luke, Jason, Anthony Olszanski, Igor Puzanov, Christos Fountzilas, Lee Rosen, Dan Lu, Adrian Hackett i in. "512 Phase I dose escalation of KD033, a PDL1-IL15 bispecific molecule, in metastatic and advanced solid tumors". Journal for ImmunoTherapy of Cancer 9, Suppl 2 (listopad 2021): A543. http://dx.doi.org/10.1136/jitc-2021-sitc2021.512.

Pełny tekst źródła

Streszczenie:

BackgroundWhile IL-2 and IL-15 signal through the shared IL-2/15 βγ receptor, IL-15 does not directly expand regulatory T cells (Tregs)or mediate activation-induced cell death and may have an improved therapeutic index. KD033 is a fusion antibody combining a fully human, high affinity anti-human Programmed Death Ligand 1 (PD-L1) IgG1 antibody with the human IL-15 receptor alpha (IL15Rα) sushi domain and human IL-15 (IL-15). KD033 and its mouse cross-reactive surrogate molecule, srKD033, have been extensively characterized in multiple in vitro and in vivo nonclinical studies and have demonstrated robust efficacy and therapeutic benefits compared to IL-15 alone.MethodsThis is a phase 1, open-label, multiple ascending dose, multi-center clinical trial being conducted in patients with metastatic or locally advanced solid tumors (NCT04242147). The primary objective is to determine the safety, tolerability, and MTD of KD033. Secondary objectives include characterization of PK and immunogenicity, evaluation of CD8+ T and NK cell activation, and assessment of best overall response and duration of response. KD033 is administered by IV infusion over 30 minutes every 14 days. The study design follows 3+3 escalation investigating dose ranges from 3µg/kg to 600µg/kg.ResultsA total of 12 patients have received treatment. Three patients were dosed in Cohort 1 (C1), four patients were dosed in Cohort 2 (C2), and three patients were dosed in Cohort 3 (C3). Two patients in Cohort 4 (C4) have been dosed. Through three dose escalation cohorts (3 µg/kg – 50 µg/kg), no dose-limiting toxicities have been reported. Grade 1–2 treatment-related toxicities resolved within 24 hours with supportive management. Grade 4 decreases in lymphocytes were noted the day after dosing in C3 and C4, which resolved on day 3 and were expected. One patient (adenoid cystic carcinoma) in C1 was shown to have stable disease for more than 6 months and one patient (metastatic gastric adenocarcinoma) in C3 was shown to have stable disease for more than 4 months.ConclusionsTo date, KD033 has been well tolerated in all subjects with on-mechanism pharmacodynamics consistent with IL-15 agonism.Ethics ApprovalThis study obtained ethics approval from WIRB.

Style APA, Harvard, Vancouver, ISO itp.

40

Pandey, Richa, Julia Zella, Margaret Clagett-Dame, Lori A. Plum, Hector F. DeLuca i Daniel W. Coyne. "Use of 2MD, a Novel Oral Calcitriol Analog, in Hemodialysis Patients with Secondary Hyperparathyroidism". American Journal of Nephrology 43, nr 3 (2016): 213–20. http://dx.doi.org/10.1159/000445756.

Pełny tekst źródła

Streszczenie:

Background: Use of existing therapies for secondary hyperparathyroidism (SHPT), such as calcitriol or paricalcitol, is frequently limited by the development of hypercalcemia. 2-Methylene-19-nor-(20S)-1α,25-dihydroxyvitamin D3 (2MD; DP001) is a novel and a more potent vitamin D receptor activator (VDRA) that more selectively localizes in the parathyroid gland, and has a wider therapeutic margin in the uremic rat model than calcitriol and paricalcitol. Design, Setting, Participants, and Measurements: Hemodialysis patients were enrolled and dosed with 110, 220, 330, 440, or 550 ng of 2MD orally thrice weekly for 4 weeks. Responders were defined as patients having a ≥30% reduction in parathyroid hormone (PTH) from baseline, and were assessed at weeks 2 and 4. Results: Of 31 patients recruited, 24 completed the 4-week treatment. There was little or no reduction in PTH in the 110 and 220 ng dose cohorts. Higher dose cohorts had greater PTH suppression with more than half the patients in the 440 and 550 ng dose cohorts considered responders (≥30% PTH reduction from baseline). None had oversuppression of PTH or hypercalcemia (corrected serum calcium >10.6 mg/dl). Plasma drug concentration increased with increasing dose, and all responders achieved a 2MD concentration of ≥1.5 pg/ml. All dose levels of 2MD were well tolerated without safety concerns. Conclusions: In hemodialysis patients with SHPT, 2MD, at thrice weekly oral doses of 440 and 550 ng, is well tolerated and effectively suppresses PTH without hypercalcemia. Future studies are needed to study the long-term implications of treating ESRD patients with this novel VDRA.

Style APA, Harvard, Vancouver, ISO itp.

41

Siiskonen, T., i M. Tapiovaara. "Weighting of secondary radiations in organ dose calculations". Radiation Protection Dosimetry 141, nr 1 (17.05.2010): 18–26. http://dx.doi.org/10.1093/rpd/ncq149.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

42

Morrell, Dean S., Eric Challgren, Mary Eapen i Nancy B. Esterly. "Bullous Acral Erythema Secondary to High-Dose Methotrexate". Journal of Pediatric Hematology/Oncology 24, nr 3 (marzec 2002): 240. http://dx.doi.org/10.1097/00043426-200203000-00018.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

43

Binns, P. J., i J. H. Hough. "Secondary Dose Exposures During 200 MeV Proton Therapy". Radiation Protection Dosimetry 70, nr 1 (1.04.1997): 441–44. http://dx.doi.org/10.1093/oxfordjournals.rpd.a031993.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

44

Tunio, Mutahir A., Mushabbab Al Asiri i Sajid Khan Durrani. "Hand Foot Syndrome Secondary to Low Dose Docetaxel". International Journal of Health Sciences 9, nr 3 (wrzesień 2015): 329–31. http://dx.doi.org/10.12816/0024699.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

45

Agosteo, Stefano, Claudio Birattari, Marcello Caravaggio, Marco Silari i Giampiero Tosi. "Secondary neutron and photon dose in proton therapy". Radiotherapy and Oncology 48, nr 3 (wrzesień 1998): 293–305. http://dx.doi.org/10.1016/s0167-8140(98)00049-8.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

46

Murphy, Christopher P., Elizabeth A. Harden i James M. Thompson. "Generalized Seizures Secondary to High-Dose Busulfan Therapy". Annals of Pharmacotherapy 26, nr 1 (styczeń 1992): 30–31. http://dx.doi.org/10.1177/106002809202600107.

Pełny tekst źródła

Streszczenie:

Two patients without prior histories of neurologic disorders experienced generalized seizures while receiving high-dose busulfan (total dose 16 mg/kg) as part of a preparative regimen for allogeneic bone marrow transplantation. A review of the literature revealed 14 similar occurrences. Maintenance of therapeutic blood concentrations of Phenytoin in subsequent patients at our institution has resulted in no further patients experiencing generalized seizures. Prophylactic anticonvulsant therapy should be considered in patients receiving high doses of busulfan.

Style APA, Harvard, Vancouver, ISO itp.

47

Lenz, Andreas M., Matthias Turina, Pascale Alard, Sarah A. Gardner i William G. Cheadle. "Microbial tolerance in secondary peritonitis is dose dependent". Cellular Immunology 258, nr 1 (2009): 98–106. http://dx.doi.org/10.1016/j.cellimm.2009.03.018.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

48

Job, P. K., i D. R. Haeffner. "Secondary bremsstrahlung dose rates from glancing incidence target". Review of Scientific Instruments 67, nr 9 (wrzesień 1996): 3376. http://dx.doi.org/10.1063/1.1146924.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

49

Sherazi, Saadia, i Ganapathi Parameswaran. "Fulminant Hepatic Failure Secondary to Low Dose Amiodarone". American Journal of Gastroenterology 100 (wrzesień 2005): S115. http://dx.doi.org/10.14309/00000434-200509001-00281.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

50

Monteserín, Luzdivina, Marcos Jiménez, Pedro Linares, Laura Rodríguez-Martín, Begoña Álvarez-Cuenllas, Concepción Álvarez-Cañas i Francisco Jorquera. "Acute hepatitis secondary to high-dose intravenous methylprednisolone". Gastroenterología y Hepatología (English Edition) 41, nr 8 (październik 2018): 508–9. http://dx.doi.org/10.1016/j.gastre.2018.08.007.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

Oferujemy zniżki na wszystkie plany premium dla autorów, których prace zostały uwzględnione w tematycznych zestawieniach literatury. Skontaktuj się z nami, aby uzyskać unikalny kod promocyjny!